The FDA approval marks a milestone for Merck, which acquired the pulmonary arterial hypertension treatment in 2021 through its $11.5 billion buyout of Acceleron Pharma.
What the Supreme Court’s mifepristone hearing could mean for pharma
Anti-abortion plaintiffs argued against the FDA’s expanded access to the abortion pill in a case that could have significant implications for the pharma industry.
Novo snatches heart disease biotech Cardior Pharmaceuticals for $1.1B
Novo’s acquisition of Cardior gives it access to CDR132L, a treatment for heart failure currently in a Phase 2 trial, and boosts its focus on cardiovascular.
Rx Rundown: AstraZeneca, Mirador Therapeutics, Orchard Therapeutics and more
AstraZeneca’s primary interest in this deal is in obtaining Fusion’s portfolio of next-generation radioconjugates, which show promise for treating cancers, specifically prostate cancer.
Rx Rundown: Merck, Coherus BioSciences, Boehringer Ingelheim and more